Biochemical Pharmacology volume 81, issue 1, P6-12 2011 DOI: 10.1016/j.bcp.2010.09.023 View full text
|
|
Share
Beverly A. Teicher

Abstract: The first generation of clinically useful antiangiogenic agents focused on VEGF and targets in the VEGF pathway. The strengths and limitations of these therapeutics are now clear. Some tumors do not respond to VEGF-directed therapies de novo and others become non-responsive or resistant over time by switching to other angiogenic pathways. The next generation of angiogenesis-directed therapeutics will expand the field beyond the VEGF pathway and become more disease selective. Placental growth factor, a protein …

expand abstract